Aurobindo acquires four biosimilar products under development - (Business Standard via NewsPoints Desk)

  • Aurobindo has reached a deal to purchase four investigational biosimilars from TL Biopharmaceutical for an undisclosed amount, as reported Business Standard Thursday.

  • Under the agreed terms, TL will supply all the developmental data for the four molecules, while Aurobindo will develop, commercialise and market the products globally.

  • The therapies are targeted for regulatory submissions between 2020 and 2022.

  • Aurobindo plans to initiate clinical studies of the lead compound in the transaction, a biosimilar of bevacizumab, later this year.

  • "We are impressed with the TL product development as these products are developed to the highest standards of biosimilarity," said Aurobindo managing director N Govindarajan, adding "this acquisition is in line with our strategy of investing in complex products and is an important first step towards establishing Aurobindo's global biosimilar portfolio."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.